Pharmacologic and Pharmacokinetic Assessment of Anti-TGFβ2 Aptamers in Rabbit Plasma and Aqueous Humor

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Pharmaceutical Research

• Publication date

  2006-01-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11095-005-9305-2PMID 16411148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct in vitro selection of a 2'-O-methyl aptamer to VEGF.

  2005cited by this paper
• Surgical strategies in patients with cataract and glaucoma.

  2005cited by this paper
• Pharmacokinetics and Biodistribution of Novel Aptamer Compositions

  2004cited by this paper
• Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery.

  2003cited by this paper
• Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome

  2003cited by this paper
• Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up.

  2002cited by this paper
• Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes.

  2002cited by this paper
• Anti-L-Selectin Aptamers: Binding Characteristics, Pharmacokinetic Parameters, and Activity Against an Intravascular Target In Vivo

  2000cited by this paper
• Comparison of visual field progression in patients with normal pressure glaucoma between eyes with and without visual field loss that threatens fixation

  2000cited by this paper
• Transforming Growth Factor-β1, -β2, and -β3 In Vivo: Effects on Normal and Mitomycin C–Modulated Conjunctival Scarring

  1999cited by this paper
• Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent.

  1999cited by this paper
• Transforming growth factor-beta1, -beta2, and -beta3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring.

  1999cited by this paper
• Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorouracil and mitomycin C.

  1997cited by this paper
• Adjunctive mitomycin C in primary trabeculectomy in phakic eyes.

  1995cited by this paper
• Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes.

  1991cited by this paper
• Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor.

  1991cited by this paper
• Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

  1990cited by this paper
• Comparison of the biological actions of TGF beta‐1 and TGF beta‐2: Differential activity in endothelial cells

  1988influential reference

• Aptamer-based therapy for fighting biofilm-associated infections.

  2024cites this paper
• Organ-on-a-Chip: The Future of Therapeutic Aptamer Research?

  2021cites this paper
• Towards Self-Transfecting Nucleic Acid Nanostructures for Gene Regulation.

  2019cites this paper
• Nanoparticles Advancing Cancer Immunotherapy

  2019cites this paper
• PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures

  2018cites this paper
• Aptamer‐based targeted therapy

  2018cites this paper
• Nucleic Acid Aptamers: New Tools in Diagnosis and Therapy

  2018cites this paper
• Pharmacokinetics, pharmacodynamics and safety of aptamers

  2018cites this paper
• Managing Intraocular Pressure: Innovation in Glaucoma Management Managing Intraocular Pressure: Innovation in Glaucoma Management

  2016cites this paper
• Managing Intraocular Pressure: Innovation in Glaucoma Management

  2016cites this paper
• Cancer immunotherapy via nucleic acid aptamers.

  2015cites this paper
• Aptamer-Drug Conjugates.

  2015cites this paper
• Pharmacokinetics of a Cholesterol-conjugated Aptamer Against the Hepatitis C Virus (HCV) NS5B Protein

  2015cites this paper
• Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases.

  2014cites this paper
• Biofunctionalization of Hydrogels for Engineering the Cellular Microenvironment

  2014cites this paper
• Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors.

  2013cites this paper
• PEI protected aptamer molecular probes for contrast-enhanced in vivo cancer imaging.

  2012cites this paper
• The Pharmacokinetics Research of Nucleic Acid Drugs

  2011cites this paper
• Discovery and development of therapeutic aptamers.

  2010cites this paper
• The Chemical Biology of Aptamers: Synthesis and Applications

  2010cites this paper
• Darwinian molecular imaging

  2009cites this paper
• The chemical biology of aptamers.

  2009cites this paper
• Recent Perspectives in Ocular Drug Delivery

  2009cites this paper
• Die chemische Biologie von Aptameren

  2009cites this paper
• Characterization of PEGylated Anti-VEGF aptamers using surface plasmon resonance

  2008cites this paper
• Aptamers in Immunotherapy

  2008cites this paper
• Aptamers and Their Potential as Recognition Elements for the Detection of Bacteria

  2008cites this paper
• Recent progress in oligonucleotide therapeutics: antisense to aptamers

  2008cites this paper
• Function and dynamics of aptamers: A case study on the malachite green aptamer

  2008cites this paper
• A Novel Branch-Type PEGylation of Aptamer Therapeutics

  2007cites this paper
• Bioconjugation of Oligonucleotides for Treating Liver Fibrosis

  2007cites this paper
• Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics

  2007cites this paper
• Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

  2007cites this paper
• Characterisation of aptamers for therapeutic studies

  2007cites this paper
• Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.

  2006cites this paper